Amyotrophic Lateral Sclerosis
- 1 January 2003
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 63 (3) , 289-310
- https://doi.org/10.2165/00003495-200363030-00004
Abstract
Fifteen years ago, a role for excitotoxic damage in the pathology of amyotrophic lateral sclerosis (ALS) was postulated. This stimulated the development of riluzole, the only available treatment for...This publication has 237 references indexed in Scilit:
- Therapeutic benefit of polyamine-modified catalase as a scavenger of hydrogen peroxide and nitric oxide in familial amyotrophic lateral sclerosis transgenicsAnnals of Neurology, 2000
- A Specific Inhibitor of Janus Kinase-3 Increases Survival in a Transgenic Mouse Model of Amyotrophic Lateral SclerosisBiochemical and Biophysical Research Communications, 2000
- Therapeutic Benefits of Putrescine-Modified Catalase in a Transgenic Mouse Model of Familial Amyotrophic Lateral SclerosisExperimental Neurology, 1999
- The effect of the nonpeptide neurotrophic compound SR 57746A on the progression of the disease state of the pmn mouseBritish Journal of Pharmacology, 1998
- Stability of Mutant Superoxide Dismutase-1 Associated with Familial Amyotrophic Lateral Sclerosis Determines the Manner of Copper Release and Induction of Thioredoxin in ErythrocytesBiochemical and Biophysical Research Communications, 1997
- Glutamate transporter gene expression in amyotrophic lateral sclerosis motor cortexAnnals of Neurology, 1996
- Works in progress abstractsAnnals of Neurology, 1995
- A Controlled Trial of Riluzole in Amyotrophic Lateral SclerosisNew England Journal of Medicine, 1994
- Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiationAnnals of Neurology, 1994
- Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosisNature, 1993